Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can your own blood speed up gum healing?

NCT ID NCT07785349

Disease control Sponsor: Şeyma Çardakçı Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This trial tests whether applying a gel made from a patient's own blood—called injectable platelet-rich fibrin (i-PRF)—to the surgical site after gum removal surgery (gingivectomy) improves healing. In a split-mouth design, one side of the mouth receives i-PRF, while the other side gets standard surgery alone. The study measures gum health and healing-related substances in the fluid around the teeth over 28 days. It includes 31 people aged 15–50 with symmetric gum overgrowth.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
injectable platelet-rich fibrin (i-PRF), a biological material made from the patient's own blood, applied to the surgical site after gingivectomy
What this could lead to
If i-PRF improves healing, it could become a simple, low-cost addition to gum surgery, reducing pain and speeding recovery.
What could go wrong
This is a small, early-stage trial (31 people) with short follow-up. Results may not apply to everyone, and i-PRF may not offer significant benefit over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

31 people

The number who actually took part.

Started

Sep 2022

Finished

Sep 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:Achieving an optimal level of oral hygiene following Phase I periodontal therapy * Presence of bilateral, symmetric chronic inflammatory gingival overgrowth in the anterior mandibular or maxillary region * Absence of attachment loss and bone loss at the surgical site * Absence of systemic conditions that could affect wound healing and periodontal surgical outcomes, such as uncontrolled diabetes, cancer, HIV, or metabolic bone diseases * No use of systemic corticosteroids, immunosuppressive agents, radiotherapy, and/or chemotherapy prescribed or taken within 2 months prior to the study intervention, which could affect study outcomes, wound healing, and the coagulation mechanism * Normal physiological hormonal balance Exclusion Criteria: Patients unable to achieve optimal oral hygiene or with poor compliance/communication * Presence of any systemic disease adversely affecting periodontal health and post-procedural wound healing (e.g., diabetes, rheumatoid arthritis, neurological disorders, pulmonary and renal diseases) * Use of medications known to cause gingival overgrowth, including immunosuppressants, anticonvulsants, and calcium channel blockers * Pregnancy or lactation in female participants * Presence of moderate to advanced gingivitis or periodontitis * Current smoking

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gingival hyperplasia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Gingival Hyperplasia gingival overgrowth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gingival hyperplasia Gingival overgrowth

Contacts and locations

Locations

  • Afyonkarahisar Health Sciences University, Faculty of Dentistry

    Ankara, None Selected, 06220, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.